NL300720I2 - - Google Patents

Download PDF

Info

Publication number
NL300720I2
NL300720I2 NL300720C NL300720C NL300720I2 NL 300720 I2 NL300720 I2 NL 300720I2 NL 300720 C NL300720 C NL 300720C NL 300720 C NL300720 C NL 300720C NL 300720 I2 NL300720 I2 NL 300720I2
Authority
NL
Netherlands
Application number
NL300720C
Other languages
Dutch (nl)
Other versions
NL300720I1 (https=
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34956036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300720(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of NL300720I2 publication Critical patent/NL300720I2/nl
Publication of NL300720I1 publication Critical patent/NL300720I1/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Wrappers (AREA)
NL300720C 2004-05-31 2015-02-19 NL300720I1 (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Publications (2)

Publication Number Publication Date
NL300720I2 true NL300720I2 (https=) 2016-01-07
NL300720I1 NL300720I1 (https=) 2016-01-07

Family

ID=34956036

Family Applications (2)

Application Number Title Priority Date Filing Date
NL1029151A NL1029151C2 (nl) 2004-05-31 2005-05-31 Combinaties die antimuscarineagentia en beta-adrenerge agonisten omvatten.
NL300720C NL300720I1 (https=) 2004-05-31 2015-02-19

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL1029151A NL1029151C2 (nl) 2004-05-31 2005-05-31 Combinaties die antimuscarineagentia en beta-adrenerge agonisten omvatten.

Country Status (45)

Country Link
US (41) US20050288266A1 (https=)
EP (14) EP2774623B1 (https=)
JP (8) JP5049120B2 (https=)
KR (3) KR20130027586A (https=)
CN (8) CN1960761A (https=)
AR (1) AR049066A1 (https=)
AT (3) ATE424847T1 (https=)
AU (3) AU2005247108B2 (https=)
BE (1) BE1016608A5 (https=)
BR (6) BRPI0511662B8 (https=)
CA (3) CA2569077C (https=)
CH (1) CH696962A5 (https=)
CL (1) CL2011000607A1 (https=)
CY (7) CY1108885T1 (https=)
DE (3) DE602005022497D1 (https=)
DK (5) DK1763369T3 (https=)
EC (6) ECSP067034A (https=)
ES (7) ES2257152B1 (https=)
FR (2) FR2870744B1 (https=)
GB (1) GB2419819B (https=)
GR (1) GR1006045B (https=)
HR (4) HRP20090107T3 (https=)
HU (2) HUP0600139A3 (https=)
IL (3) IL179687A (https=)
IT (1) ITMI20051021A1 (https=)
LT (1) LTC1763368I2 (https=)
LU (1) LU91214B1 (https=)
MC (1) MC200083A1 (https=)
ME (4) ME01670B (https=)
MX (3) MXPA06013847A (https=)
MY (1) MY142095A (https=)
NL (2) NL1029151C2 (https=)
NO (7) NO20065477L (https=)
NZ (3) NZ551668A (https=)
PE (3) PE20060292A1 (https=)
PL (6) PL2292267T3 (https=)
PT (4) PT1763368E (https=)
RS (4) RS53529B1 (https=)
RU (4) RU2373935C2 (https=)
SI (5) SI1763369T1 (https=)
TW (1) TWI404530B (https=)
UA (6) UA86976C2 (https=)
UY (1) UY28933A1 (https=)
WO (3) WO2005115466A1 (https=)
ZA (6) ZA200600261B (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100471016B1 (ko) * 1996-08-07 2005-07-12 스미또모 가가꾸 가부시키가이샤 살충성에어로졸조성물및이를제조하기위한살충조성물
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
MXPA06001046A (es) * 2003-07-29 2006-04-24 Boehringer Ingelheim Int Combinacion de un anticolinergico y un esteroide y su uso para tratar trastornos respiratorios por inhalacion.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
PT1891974E (pt) * 2004-05-31 2010-09-27 Almirall Sa Combinações que compreendem agentes anti-muscarínicos e inibidores de pde4
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JPWO2006085689A1 (ja) * 2005-02-10 2008-06-26 オンコリスバイオファーマ株式会社 テロメライシン併用抗癌剤
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP1996179A2 (en) * 2006-02-22 2008-12-03 Valorisation-Recherche, Limited Partnership Compositions for disorders associated with metachromatic cell activation
US8007790B2 (en) * 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
ES2443342T3 (es) * 2006-07-05 2014-02-19 Takeda Gmbh Combinación de inhibidor de la HMG-CoA reductasa rosuvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast, roflumilast-N-óxido para el tratamiento de enfermedades pulmonares inflamatorias
CA2657639A1 (en) 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
UA98136C2 (ru) * 2007-02-21 2012-04-25 Алмиралл, С.А. Применение аклидиния для лечения респираторных заболеваний
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
RU2487131C2 (ru) * 2008-03-14 2013-07-10 Оцука Фармасьютикал Ко., Лтд. Ингибитор ммр-2 и/или ммр-9
MX2010012492A (es) 2008-05-27 2010-12-21 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PT3061821T (pt) 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PE20130601A1 (es) 2010-08-03 2013-05-30 Chiesi Farma Spa Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112013030302B1 (pt) 2011-06-10 2021-08-24 Chiesi Farmaceutici S.P.A. Composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
ME02297B (me) 2011-06-10 2016-02-20 Chiesi Farm Spa Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
EA026267B1 (ru) * 2012-01-25 2017-03-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
US9156833B2 (en) 2012-07-16 2015-10-13 Barry University, Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
BR112015012730B1 (pt) 2012-12-06 2022-07-05 Chiesi Farmaceutici S.P.A. Composto, composição farmaceutica, dispositivo, uso de um composto e combinação
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
EP2968312B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
CN106029931A (zh) * 2013-10-09 2016-10-12 怡康医疗股份有限公司 用于医疗装置的改善的金属合金
BR112016010416B1 (pt) 2013-11-15 2021-10-05 Performance Polyamides, Sas Composição de poliamida, e componente de metal
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102794286B1 (ko) * 2016-01-08 2025-04-09 테론 파마슈티칼즈, 인크. 7-아조니아바이사이클로[2.2.1]헵탄 유도체의 건조 분말 흡입기 조성물
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
US20240270701A1 (en) * 2021-09-23 2024-08-15 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) * 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) * 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) * 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
ATE177941T1 (de) * 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
DK0674533T3 (da) 1992-12-18 1999-09-27 Schering Corp Inhalator for medikamenter i pulverform
GB9412434D0 (en) * 1994-06-21 1994-08-10 Inmos Ltd Computer instruction compression
TR199701169T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
JP4672143B2 (ja) * 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) * 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
DE60125026T2 (de) * 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU2001289652A1 (en) * 2000-06-28 2002-01-08 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6706726B2 (en) * 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
CA2436540C (en) 2000-10-31 2008-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
AU2002314102A1 (en) * 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) * 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US7094788B2 (en) * 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BR0310084A (pt) * 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
CA2487399A1 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
AU2002345266B2 (en) * 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
WO2004047817A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) * 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
WO2004084896A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
CA2519682A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
ES2284025T3 (es) * 2003-07-29 2007-11-01 Boehringer Ingelheim International Gmbh Medicamentos para inhalar que comprenden betamimeticos y un anticolinergico.
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
ES2309705T3 (es) * 2004-02-06 2008-12-16 MEDA PHARMA GMBH &amp; CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
EP1713471B1 (en) * 2004-02-06 2012-01-18 MEDA Pharma GmbH & Co. KG Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
US7375935B2 (en) * 2004-04-12 2008-05-20 Leviton Manufacturing Co., Inc. Ground fault circuit interrupter with enhanced radio frequency interference suppression
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens

Also Published As

Publication number Publication date
IL179689A0 (en) 2007-05-15
ZA200609985B (en) 2008-09-25
ZA200609989B (en) 2007-11-28
BRPI0511662B8 (pt) 2021-05-25
SI1891973T1 (sl) 2010-11-30
ATE424847T1 (de) 2009-03-15
GR20050100269A (el) 2005-12-31
US20180200234A1 (en) 2018-07-19
ES2293849A1 (es) 2008-03-16
EP2774622B1 (en) 2015-03-11
BRPI0511662B1 (pt) 2019-02-19
CA2533061A1 (en) 2005-12-08
US20120088743A1 (en) 2012-04-12
US20110021478A1 (en) 2011-01-27
UA89181C2 (ru) 2010-01-11
US20120071452A1 (en) 2012-03-22
DK1765404T3 (da) 2009-03-16
ECSP067037A (es) 2006-12-29
ES2293849B2 (es) 2009-04-16
JP2008500988A (ja) 2008-01-17
CN1960759A (zh) 2007-05-09
CY1109139T1 (el) 2014-07-02
US20130310354A1 (en) 2013-11-21
BRPI0511666A (pt) 2008-01-02
US20130035319A1 (en) 2013-02-07
EP1891973A1 (en) 2008-02-27
EP2002844B1 (en) 2010-12-29
JP4928258B2 (ja) 2012-05-09
NO334337B1 (no) 2014-02-10
GR1006045B (el) 2008-09-08
ES2322280T5 (es) 2013-12-03
US20170049756A1 (en) 2017-02-23
RU2404771C3 (ru) 2018-03-12
CN1960761A (zh) 2007-05-09
IL179687A (en) 2011-11-30
JP2008500990A (ja) 2008-01-17
US20090099148A1 (en) 2009-04-16
US20150306079A1 (en) 2015-10-29
PE20081649A1 (es) 2008-11-28
JP2012184272A (ja) 2012-09-27
IL179684A (en) 2011-11-30
EP2292267A3 (en) 2011-06-15
NO20065476L (no) 2006-12-28
US20080051378A1 (en) 2008-02-28
RU2373935C2 (ru) 2009-11-27
UY28933A1 (es) 2005-08-31
NO2015007I1 (no) 2015-03-09
US20140296197A1 (en) 2014-10-02
BE1016608A5 (fr) 2007-02-06
KR20070024556A (ko) 2007-03-02
HRP20100489T1 (hr) 2010-10-31
PL1763369T3 (pl) 2009-06-30
FR2870744B1 (fr) 2006-12-08
EP1765404A1 (en) 2007-03-28
NO338621B1 (no) 2016-09-19
EP2319538A2 (en) 2011-05-11
AU2005247103B2 (en) 2010-10-28
CN1972716A (zh) 2007-05-30
CN1960759B (zh) 2011-07-13
NO20065483L (no) 2006-12-22
ZA200609990B (en) 2007-12-27
ZA200600261B (en) 2007-04-25
NO2015007I2 (no) 2015-12-21
SI1763368T2 (sl) 2013-12-31
BRPI0511656A (pt) 2008-01-02
US20150202213A1 (en) 2015-07-23
PL1765404T3 (pl) 2009-06-30
ZA200609986B (en) 2007-11-28
HRP20090215T4 (hr) 2013-12-20
NL1029151A1 (nl) 2005-12-05
NO20065478L (no) 2006-12-28
CA2568566A1 (en) 2005-12-08
RS53529B1 (sr) 2015-02-27
IE20050366A1 (en) 2005-11-30
NO20065477L (no) 2006-12-22
CY1109938T1 (el) 2014-09-10
US20120040943A1 (en) 2012-02-16
JP5133054B2 (ja) 2013-01-30
ES2322280T3 (es) 2009-06-18
AU2005247107A1 (en) 2005-12-08
CY1108902T1 (el) 2014-07-02
PL2292267T3 (pl) 2015-03-31
UA89183C2 (ru) 2010-01-11
TWI404530B (zh) 2013-08-11
DK1763369T3 (da) 2009-03-16
RU2465902C2 (ru) 2012-11-10
IL179689A (en) 2012-02-29
US20060154934A1 (en) 2006-07-13
HK1125573A1 (en) 2009-08-14
HRP20090107T3 (en) 2009-03-31
MC200083A1 (fr) 2005-12-07
CH696962A5 (fr) 2008-02-29
RS50787B2 (sr) 2018-02-28
JP2008500987A (ja) 2008-01-17
HK1090306A1 (en) 2006-12-22
IL179687A0 (en) 2007-05-15
EP2002845A3 (en) 2009-02-25
GB2419819A (en) 2006-05-10
HRP20140864T1 (hr) 2014-12-05
CY1110798T1 (el) 2015-06-10
EP1763369A1 (en) 2007-03-21
KR20130027586A (ko) 2013-03-15
CA2533061C (en) 2008-07-08
HRP20090215T1 (en) 2009-05-31
CY1115669T1 (el) 2017-01-25
EP2002843A2 (en) 2008-12-17
US20160038470A1 (en) 2016-02-11
UA89185C2 (ru) 2010-01-11
CL2011000607A1 (es) 2011-08-19
US20100056486A1 (en) 2010-03-04
ES2348680T3 (es) 2010-12-10
DK1763368T3 (da) 2009-05-04
US20140094442A1 (en) 2014-04-03
EP2210613A1 (en) 2010-07-28
PT1763368E (pt) 2009-05-14
PT2292267E (pt) 2014-10-15
US20120302532A1 (en) 2012-11-29
HUP0600139A2 (en) 2007-06-28
PE20060292A1 (es) 2006-04-14
US20110021477A1 (en) 2011-01-27
HK1095757A1 (en) 2007-05-18
MXPA06013847A (es) 2007-03-01
EP2138188A1 (en) 2009-12-30
JP5049120B2 (ja) 2012-10-17
UA89184C2 (ru) 2010-01-11
US20120309727A1 (en) 2012-12-06
EP1763368B2 (en) 2013-08-21
CN102755321A (zh) 2012-10-31
EP1891973B1 (en) 2010-07-21
US20060189651A1 (en) 2006-08-24
EP1761280A1 (en) 2007-03-14
US20070232637A1 (en) 2007-10-04
NL300720I1 (https=) 2016-01-07
JP5538485B2 (ja) 2014-07-02
AU2005247107B2 (en) 2010-10-28
CN1960762A (zh) 2007-05-09
EP1763368A1 (en) 2007-03-21
AU2005247108A1 (en) 2005-12-08
BRPI0511669A (pt) 2008-01-02
SI21784A (sl) 2005-12-31
RU2006147250A (ru) 2008-07-20
GB0526502D0 (en) 2006-02-08
ES2257152B1 (es) 2007-07-01
ATE474600T1 (de) 2010-08-15
AU2005247103A1 (en) 2005-12-08
US20080045565A1 (en) 2008-02-21
US20200009117A1 (en) 2020-01-09
EP2774623A1 (en) 2014-09-10
GB2419819B (en) 2007-02-21
ES2257152A1 (es) 2006-07-16
DE602005022497D1 (de) 2010-09-02
PL379660A1 (pl) 2006-11-13
AR049066A1 (es) 2006-06-21
CN102085373A (zh) 2011-06-08
KR20070018105A (ko) 2007-02-13
HUP0600139A3 (en) 2010-12-28
JP2006527183A (ja) 2006-11-30
US20060205702A1 (en) 2006-09-14
DK2292267T3 (da) 2014-09-15
ES2505329T3 (es) 2014-10-09
US20090176751A1 (en) 2009-07-09
EP1763369B1 (en) 2008-12-17
FR15C0017I1 (https=) 2015-03-04
PL1763368T5 (pl) 2014-01-31
BRPI0511667A (pt) 2008-01-02
NO20065482L (no) 2006-12-22
MXPA06004124A (es) 2006-06-27
US20140148420A1 (en) 2014-05-29
CY1108885T1 (el) 2014-07-02
RU2006142331A (ru) 2008-06-20
DE602005011803D1 (de) 2009-01-29
WO2005115466A1 (en) 2005-12-08
JP5032984B2 (ja) 2012-09-26
EP2002844A2 (en) 2008-12-17
EP2002843A3 (en) 2009-04-08
CY2015006I2 (el) 2016-06-22
RU2404771C2 (ru) 2010-11-27
EP1765404B1 (en) 2008-12-31
NZ551668A (en) 2010-06-25
RS50787B (sr) 2010-08-31
BRPI0511662A (pt) 2008-01-02
NZ544539A (en) 2007-09-28
ECSP067035A (es) 2006-12-29
EP2292267B1 (en) 2014-07-23
RU2006147268A (ru) 2008-07-20
ME02779B (me) 2010-06-30
ECSP067036A (es) 2006-12-29
ECSP067038A (es) 2006-12-29
CN1960760A (zh) 2007-05-09
IL179684A0 (en) 2007-05-15
US20150080359A1 (en) 2015-03-19
US20090111785A1 (en) 2009-04-30
ZA200609987B (en) 2007-12-27
UA86976C2 (ru) 2009-06-10
MXPA06013848A (es) 2007-03-01
WO2005115462A1 (en) 2005-12-08
RU2010129940A (ru) 2012-01-27
JP2012012407A (ja) 2012-01-19
US20050267135A1 (en) 2005-12-01
US20090093503A1 (en) 2009-04-09
US20080146603A1 (en) 2008-06-19
JP2008500986A (ja) 2008-01-17
NO20065479L (no) 2006-12-22
US20110021476A1 (en) 2011-01-27
RS51386B (sr) 2011-02-28
US20050267078A1 (en) 2005-12-01
AU2005247108B2 (en) 2008-09-11
RU2385721C2 (ru) 2010-04-10
NL1029151C2 (nl) 2006-06-22
LTC1763368I2 (lt) 2016-12-27
ECSP067034A (es) 2006-12-29
BRPI0511660A (pt) 2008-01-02
CA2569077C (en) 2012-12-18
NZ551667A (en) 2010-07-30
CY2015006I1 (el) 2016-06-22
DE602005013220D1 (de) 2009-04-23
ES2318498T3 (es) 2009-05-01
US20100048615A1 (en) 2010-02-25
KR101256417B1 (ko) 2013-04-22
HK1198120A1 (en) 2015-03-13
US20130252928A1 (en) 2013-09-26
US20120309726A1 (en) 2012-12-06
ATE417627T1 (de) 2009-01-15
DK1891973T3 (da) 2010-10-18
SI2292267T1 (sl) 2014-11-28
EP2774623B1 (en) 2015-04-08
LU91214B1 (fr) 2006-01-26
RS50717B (sr) 2010-06-30
SI1763368T1 (sl) 2009-08-31
FR15C0017I2 (fr) 2015-11-13
SI1763369T1 (sl) 2009-06-30
EP1763368B1 (en) 2009-03-11
JP5107701B2 (ja) 2012-12-26
PL1763368T3 (pl) 2009-08-31
UA89182C2 (ru) 2010-01-11
ME01680B (me) 2010-08-31
FR2870744A1 (fr) 2005-12-02
CN102755321B (zh) 2015-07-15
PL1891973T3 (pl) 2010-11-30
ME01670B (me) 2010-06-30
WO2005115467A1 (en) 2005-12-08
PT1763369E (pt) 2009-02-26
ES2348558T3 (es) 2010-12-09
HUS1500011I1 (hu) 2018-09-28
WO2005115466A8 (en) 2007-01-04
KR101174677B1 (ko) 2012-08-17
PT1891973E (pt) 2010-09-27
EP2774622A1 (en) 2014-09-10
ECSP067033A (es) 2006-12-29
CA2568566C (en) 2012-12-18
EP2319538A3 (en) 2011-06-15
PE20081650A1 (es) 2008-12-06
US20100048616A1 (en) 2010-02-25
ME02134B (me) 2015-02-27
US20050288266A1 (en) 2005-12-29
EP2002844A3 (en) 2009-03-04
CA2569077A1 (en) 2005-12-08
US20120059031A1 (en) 2012-03-08
TW200608971A (en) 2006-03-16
US20070167489A1 (en) 2007-07-19
EP2292267A2 (en) 2011-03-09
ITMI20051021A1 (it) 2005-12-01
JP4966192B2 (ja) 2012-07-04
DK1763368T4 (da) 2013-11-04
JP2008500989A (ja) 2008-01-17
EP2002845A2 (en) 2008-12-17
MY142095A (en) 2010-09-15
CN101018566A (zh) 2007-08-15

Similar Documents

Publication Publication Date Title
BE2024C508I2 (https=)
BE2023C542I2 (https=)
BE2022C549I2 (https=)
BE2021C001I2 (https=)
BE2020C513I2 (https=)
BE2020C517I2 (https=)
BE2019C540I2 (https=)
BE2019C523I2 (https=)
BE2019C548I2 (https=)
BE2019C506I2 (https=)
BE2020C525I2 (https=)
BE2018C045I2 (https=)
BE2017C063I2 (https=)
BE2017C027I2 (https=)
BE2017C023I2 (https=)
BE2017C002I2 (https=)
BE2016C067I2 (https=)
BE2016C014I2 (https=)
BE2015C041I2 (https=)
BE2015C038I2 (https=)
BE2015C014I2 (https=)
BE2014C071I2 (https=)
BE2015C015I2 (https=)
BE2014C064I2 (https=)
BE2014C063I2 (https=)